Jenkins Valerie, Shilling Valerie, Fallowfield Lesley, Howell Anthony, Hutton Sam
Cancer Research UK, Brighton and Sussex Medical School, University of Sussex, Brighton, UK.
Psychooncology. 2004 Jan;13(1):61-6. doi: 10.1002/pon.709.
This pilot study examines whether hormone therapy for breast cancer affects cognition. Patients participating in a randomised trial of anastrozole, tamoxifen alone or combined (ATAC) (n=94) and a group of women without breast cancer (n=35) completed a battery of neuropsychological measures. Compared with the control group, the patients were impaired on a processing speed task (p=0.032) and on a measure of immediate verbal memory (p=0.026) after controlling for the use of hormone replacement therapy in both groups. Patient group performance was not significantly related to length of treatment or measures of psychological morbidity. The results showed specific impairments in processing speed and verbal memory in women receiving hormonal therapy for the treatment of breast cancer. Verbal memory may be especially sensitive to changes in oestrogen levels, a finding commonly reported in studies of hormone replacement therapy in healthy women. In view of the increased use of hormone therapies in an adjuvant and preventative setting their impact on cognitive functioning should be investigated more thoroughly.
这项初步研究探讨了乳腺癌激素疗法是否会影响认知。参与阿那曲唑、他莫昔芬单药或联合用药（ATAC）随机试验的患者（n = 94）以及一组无乳腺癌的女性（n = 35）完成了一系列神经心理学测试。在控制两组激素替代疗法的使用情况后，与对照组相比，患者在处理速度任务（p = 0.032）和即时言语记忆测试（p = 0.026）中表现受损。患者组的表现与治疗时长或心理疾病测量指标无显著相关性。结果显示，接受激素疗法治疗乳腺癌的女性在处理速度和言语记忆方面存在特定损伤。言语记忆可能对雌激素水平变化尤为敏感，这一发现常见于健康女性激素替代疗法的研究中。鉴于激素疗法在辅助和预防治疗中的使用增加，应更全面地研究其对认知功能的影响。
